Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Cash from Operations (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Cash from Operations for 15 consecutive years, with 2927347.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 72.24% year-over-year to 2927347.0, compared with a TTM value of 10717499.0 through Sep 2025, down 43.46%, and an annual FY2024 reading of 8200000.0, down 27.52% over the prior year.
  • Cash from Operations was 2927347.0 for Q3 2025 at BioRestorative Therapies, down from 2693867.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 629364.0 in Q3 2021 and bottomed at 2927347.0 in Q3 2025.
  • Average Cash from Operations over 5 years is 1698590.47, with a median of 1594634.0 recorded in 2022.
  • The sharpest move saw Cash from Operations tumbled 130.65% in 2022, then rose 18.75% in 2023.
  • Year by year, Cash from Operations stood at 1145014.0 in 2021, then crashed by 41.11% to 1615688.0 in 2022, then grew by 1.72% to 1587962.0 in 2023, then crashed by 45.94% to 2317499.0 in 2024, then decreased by 26.31% to 2927347.0 in 2025.
  • Business Quant data shows Cash from Operations for BRTX at 2927347.0 in Q3 2025, 2693867.0 in Q2 2025, and 2778786.0 in Q1 2025.